INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
Integrated Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Market Cap | $5.59M | $166.30M |
| Enterprise Value | $1.12M | $88.19M |
| PS Ratio | 0.13 | 3.65 |
| PB Ratio | 0.32 | 2.03 |
| P/TBV Ratio | 0.32 | 2.29 |
| P/FCF Ratio | 6.25 | 17.44 |
| P/OCF Ratio | 4.51 | 12.98 |
Enterprise value
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| EV / Sales | 0.03 | 2.51 |
| EV / FCF | 1.25 | 20.86 |
Income (trailing twelve months)
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Revenue | $43.87M | $58.34M |
| Gross Profit | $800.00K | $105.94M |
| Operating Income | -$2.71M | -$21.40M |
| Pretax Income | -$2.56M | -$14.34M |
| Net Income | -$2.84M | -$22.46M |
| EBITDA | -$2.41M | -$16.91M |
| EPS (Diluted) | -$0.09 | -$0.83 |
Margins
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Gross Margin | 1.82% | 52.9% |
| Operating Margin | -6.17% | -44.0% |
| Pretax Margin | -5.84% | -13.3% |
| Profit Margin | -6.48% | -40.2% |
| EBITDA Margin | -5.50% | -30.2% |
| FCF Margin | 2.04% | -9.27% |
Returns
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -15.0% | -53.2% |
| Return on Assets (ROA) | -11.3% | -40.9% |
| Return on Invested Capital (ROIC) | -14.3% | -32.4% |
| Return on Capital Employed (ROCE) | -13.8% | -38.1% |
Growth
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -19.3% | 5.96% |
| Net Income Growth (YoY) | -451.7% | -35.2% |
| EPS Growth (YoY) | -400.0% | -26.2% |
| FCF Growth (YoY) | -52.2% | 2.34% |
| Revenue Growth (3Y CAGR) | -4.69% | 2.25% |
| Revenue Growth (5Y CAGR) | -7.15% | 6.48% |
Balance sheet
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.47M | $61.43M |
| Net Cash (Debt) | $4.47M | $15.35M |
| Net Cash Per Share | $0.14 | $0.66 |
| Equity (Book Value) | $17.67M | $49.09M |
| Book Value Per Share | $0.57 | $1.37 |
| Tangible Book Value | $17.67M | $23.52M |
| Working Capital | $11.58M | $76.81M |
Financial position
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Current Ratio | 3.00 | 3.34 |
| Quick Ratio | 1.35 | 2.44 |
| Interest Coverage | -225.42 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | $1.24M | -$12.35M |
| Capital Expenditures | -$346.00K | -$1.08M |
| Free Cash Flow | $895.00K | -$20.22M |
| FCF Per Share | $0.03 | -$0.42 |
Efficiency
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 1.75 | 0.39 |
| Inventory Turnover | 4.66 | 2.70 |
| Revenue Per Employee | $327.40K | $404.87K |
| Profits Per Employee | -$21.21K | -$703.34K |
| Employee Count | 134 | 74 |
Dividends and yields
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -50.8% | -23.3% |
| FCF Yield | 16.0% | -8.72% |
Shares
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 31,059,600 | 58,127,000 |
| Shares Change (YoY) | -0.35% | 10.9% |
| Shares Change (QoQ) | -0.11% | 0.54% |
| Float | 8,570,010 | 49,136,700 |
| Shares Held by Insiders | 72.4% | 11.6% |
Taxes
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Income Tax | $279.00K | $79.87K |
Scores
| Measure | Integrated Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | 0.47 | -0.22 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -1.18 | -2.62 |
Calculated by StockData from Integrated Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.